Format

Send to

Choose Destination
Mol Ther. 2012 Jul;20(7):1298-304. doi: 10.1038/mt.2012.79. Epub 2012 Apr 24.

In vivo gene delivery by nonviral vectors: overcoming hurdles?

Author information

1
Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7571, USA.

Abstract

The promise of cancer gene therapeutics is hampered by difficulties in the in vivo delivery to the targeted tumor cells, and systemic delivery remains to be the biggest challenge to be overcome. Here, we concentrate on systemic in vivo gene delivery for cancer therapy using nonviral vectors. In this review, we summarize the existing delivery barriers together with the requirements and strategies to overcome these problems. We will also introduce the current progress in the design of nonviral vectors, and briefly discuss their safety issues.

PMID:
22525514
PMCID:
PMC3392980
DOI:
10.1038/mt.2012.79
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center